KDR and non-small cell lung carcinoma: For example, Sunitinib, as a kinase inhibitor targeting VEGFR2 and PDGFRβ, has been observed to be sensitive to non-small cell lung cancer (NSCLC) based on newly predicted drug responses vs. available ones, as shown in Figure 7.